Literature DB >> 6681709

Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease.

I Hutton, A C Tweddel, A C Rankin, I D Walker, J F Davidson.   

Abstract

1 Plasma thromboxane levels were obtained from both the coronary sinus and aorta in patients with stable angina pectoris paced to angina, and in unstable angina patients before and after dazoxiben 100 mg. 2 Although there was a wide range of values in the different groups, dazoxiben significantly reduced plasma thromboxane levels in all patients. 3 Dazoxiben had no adverse effect on coronary and systemic haemodynamics, and atrial pacing time to angina was increased from 245 +/- 41 to 308 +/- 48s (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681709      PMCID: PMC1427691          DOI: 10.1111/j.1365-2125.1983.tb02113.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  The release of a human platelet specific protein measured by a radioimmunoassay.

Authors:  C A Ludlam; S Moore; A E Bolton; D S Pepper; J D Cash
Journal:  Thromb Res       Date:  1975-06       Impact factor: 3.944

Review 3.  Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo.

Authors:  K L Kaplan; J Owen
Journal:  Blood       Date:  1981-02       Impact factor: 22.113

4.  Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase.

Authors:  H M Tyler; C A Saxton; M J Parry
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

5.  Platelet aggregates in peripheral and coronary-sinus blood in patients with spontaneous coronary-artery spasm.

Authors:  R M Robertson; D Robertson; G C Friesinger; S Timmons; J Hawiger
Journal:  Lancet       Date:  1980-10-18       Impact factor: 79.321

6.  Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature.

Authors:  R I Lewy; L Wiener; P Walinsky; A M Lefer; M J Silver; J B Smith
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

7.  Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease.

Authors:  G Bergman; K Daly; L Atkinson; M Rothman; P J Richardson; G Jackson; D E Jewitt
Journal:  Lancet       Date:  1981-03-14       Impact factor: 79.321

8.  Thromboxane synthetase inhibition as antithrombotic strategy.

Authors:  J Vermylen; G Defreyn; L O Carreras; S J Machin; J Van Schaeren; M Verstraete
Journal:  Lancet       Date:  1981-05-16       Impact factor: 79.321

9.  Platelet activation in clinical coronary artery disease and spasm.

Authors:  M D Rubenstein; R T Wall; D S Baim; D C Harrison
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

10.  Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.

Authors:  P D Hirsh; L D Hillis; W B Campbell; B G Firth; J T Willerson
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

View more
  1 in total

1.  Effect of the specific thromboxane receptor blocking drug AH23848 in patients with angina pectoris.

Authors:  D P De Bono; P Lumley; M Been; R Keery; S E Ince; D F Woodings
Journal:  Br Heart J       Date:  1986-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.